Zobrazeno 1 - 10
of 870
pro vyhledávání: '"Fred, R Hirsch"'
Autor:
Diego deMiguel‐Perez, Marisol Arroyo‐Hernandez, Sabrina La Salvia, Muthukumar Gunasekaran, Edward M. Pickering, Stephanie Avila, Etse Gebru, Eduardo Becerril‐Vargas, Sergio Monraz‐Perez, Kapil Saharia, Alison Grazioli, Michael T. McCurdy, Matthew Frieman, Lisa Miorin, Alessandro Russo, Andrés F. Cardona, Adolfo García‐Sastre, Sunjay Kaushal, Fred R. Hirsch, Djordje Atanackovic, Susmita Sahoo, Oscar Arrieta, Christian Rolfo
Publikováno v:
Journal of Extracellular Vesicles, Vol 13, Iss 11, Pp n/a-n/a (2024)
Abstract The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) causes coronavirus disease 2019 (COVID‐19) and has been related to more than 7 million deaths globally since 2019. The association of high levels of IL‐6 with severe ca
Externí odkaz:
https://doaj.org/article/5384e96cf6444786964202fd8fdb4104
Autor:
Fred R. Hirsch, Chul Kim
Publikováno v:
Oncology and Therapy, Vol 12, Iss 2, Pp 223-231 (2024)
Abstract The identification of actionable biomarkers and development of targeted therapies have revolutionized the field of lung cancer treatment. In patients with advanced non-small cell lung cancer (NSCLC), biomarker testing can inform selection of
Externí odkaz:
https://doaj.org/article/2d8a6e562984474f9d941d9bbd39d4ae
Autor:
Diego de Miguel‑Perez, Murat Ak, Priyadarshini Mamindla, Alessandro Russo, Serafettin Zenkin, Nursima Ak, Vishal Peddagangireddy, Luis Lara‑Mejia, Muthukumar Gunasekaran, Andres F. Cardona, Aung Naing, Fred R. Hirsch, Oscar Arrieta, Rivka R. Colen, Christian Rolfo
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-6 (2024)
Abstract Background Immune-checkpoint inhibitors (ICIs) have showed unprecedent efficacy in the treatment of patients with advanced non-small cell lung cancer (NSCLC). However, not all patients manifest clinical benefit due to the lack of reliable pr
Externí odkaz:
https://doaj.org/article/aef1eb16e7a04127b7be386a1b11b7d4
Autor:
Anna Solta, Büsra Ernhofer, Kristiina Boettiger, Zsolt Megyesfalvi, Simon Heeke, Mir Alireza Hoda, Christian Lang, Clemens Aigner, Fred R. Hirsch, Karin Schelch, Balazs Döme
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-25 (2024)
Abstract Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immunotherapy. Meanwhile, recent studi
Externí odkaz:
https://doaj.org/article/9e0908a3548240cd8b1b9b99d893d136
Autor:
Yang Dawei, Stephan Lam, Kai Wang, Zhou Jian, Zhang Xiaoju, Wang Qi, Zhou Chengzhi, Zhang Lichuan, Bai Li, Wang Yuehong, Li Ming, Sun Jiayuan, Li Yang, Fengming Kong, Haiquan Chen, Ming Fan, Xuan Jianwei, Fred R. Hirsch, Charles A. Powell, Bai Chunxue
Publikováno v:
Clinical eHealth, Vol 7, Iss , Pp 27-35 (2024)
Background: The most effective method for improving the prognosis of lung cancer is the application of low-dose computed tomography (LDCT) for pulmonary nodule screening in populations at high risk. Timely diagnosis and treatment of early-stage lung
Externí odkaz:
https://doaj.org/article/e4eaf09bf0cc40e4b4d7d6eb7280af92
Autor:
Linshan Xie, Hui Kong, Jinjie Yu, Mengting Sun, Shaohua Lu, Yong Zhang, Jie Hu, Fang Du, Qiuyu Lian, Hongyi Xin, Jian Zhou, Xiangdong Wang, Charles A. Powell, Fred R. Hirsch, Chunxue Bai, Yuanlin Song, Jun Yin, Dawei Yang
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 2, Pp n/a-n/a (2024)
Abstract Background Patients who possess various histological subtypes of early‐stage lung adenocarcinoma (LUAD) have considerably diverse prognoses. The simultaneous existence of several histological subtypes reduces the clinical accuracy of the d
Externí odkaz:
https://doaj.org/article/bfde69e52a894fb2a6792d8b2ef3da13
Autor:
Shahram Tahvilian, Joshua D. Kuban, David F. Yankelevitz, Daniel Leventon, Claudia I. Henschke, Jeffrey Zhu, Lara Baden, Rowena Yip, Fred R. Hirsch, Rebecca Reed, Ashley Brown, Allison Muldoon, Michael Trejo, Benjamin A. Katchman, Michael J. Donovan, Paul C. Pagano
Publikováno v:
BMC Pulmonary Medicine, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Purpose Computed tomography is the standard method by which pulmonary nodules are detected. Greater than 40% of pulmonary biopsies are not lung cancer and therefore not necessary, suggesting that improved diagnostic tools are needed. The Lun
Externí odkaz:
https://doaj.org/article/feb9dcbc11b6453e9e9fca9316e4263d
Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer
Autor:
Philip C. Mack, Chih-Yuan Hsu, Ananda M. Rodilla, Jorge E. Gomez, Jazz Cagan, Yuanhui Huang, Sooyun Tavolacci, Rajesh M. Valanparambil, Nicholas Rohs, Rachel Brody, Brittney Nichols, Juan Manuel Carreño, Sheena Bhalla, Christian Rolfo, David E. Gerber, Amy Moore, Jennifer C. King, Rafi Ahmed, John D. Minna, Paul A. Bunn, Adolfo García-Sastre, Florian Krammer, Fred R. Hirsch, Yu Shyr
Publikováno v:
Vaccines, Vol 12, Iss 7, p 713 (2024)
In patients with lung cancer (LC), understanding factors that impact the dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike antibody (SAb) titers over time is critical, but challenging, due to evolving treatments, inf
Externí odkaz:
https://doaj.org/article/c8cc0c60eaba4193bcab4968d29b9d80
Autor:
Rajwanth Veluswamy, Fred R. Hirsch, Emanuela Taioli, Juan Wisnivesky, Ross Strauss, Douglas Harrough, Boxiong Tang, Gisoo Barnes
Publikováno v:
Cancer Medicine, Vol 11, Iss 22, Pp 4265-4272 (2022)
Abstract Background Immune checkpoint inhibitors targeting the programmed cell death protein‐1 (PD‐1) and programmed death ligand‐1 (PD‐L1) axis (collectively referred to as PD[L]1i) have demonstrated clinical benefits in non‐small cell lun
Externí odkaz:
https://doaj.org/article/1f64b72ea62f4d40a0b47d3d61bc865c
Autor:
Diego de Miguel-Perez, Alessandro Russo, Oscar Arrieta, Murat Ak, Feliciano Barron, Muthukumar Gunasekaran, Priyadarshini Mamindla, Luis Lara-Mejia, Christine B. Peterson, Mehmet E. Er, Vishal Peddagangireddy, Francesco Buemi, Brandon Cooper, Paolo Manca, Rena G. Lapidus, Ru-Ching Hsia, Andres F. Cardona, Aung Naing, Sunjay Kaushal, Fred R. Hirsch, Philip C. Mack, Maria Jose Serrano, Vincenzo Adamo, Rivka R. Colen, Christian Rolfo
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-14 (2022)
Abstract Background Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers. Liquid
Externí odkaz:
https://doaj.org/article/4c65ef22566e4f538c868b2b0b00c400